Search

Your search keyword '"Orofino, G"' showing total 313 results

Search Constraints

Start Over You searched for: Author "Orofino, G" Remove constraint Author: "Orofino, G" Language english Remove constraint Language: english
313 results on '"Orofino, G"'

Search Results

2. Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort

3. Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project

4. Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project

5. The effect of switching to Maraviroc + Darunavir/ritonavir dual therapy in virologically suppressed patients on the progression of liver fibrosis: findings from a randomized study

6. Weight Gain: A Possible Side Effect of All Antiretrovirals

7. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL

9. The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort

10. Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort

13. Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?

14. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)

15. Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study

16. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL

17. Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study

18. Factors associated with hospital admission for COVID-19 in HIV patients

19. Evaluation of HIV transmission clusters among natives and foreigners living in Italy

20. Correction to: Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression (The Patient - Patient-Centered Outcomes Research, (2020), 13, 3, (375-387), 10.1007/s40271-020-00413-y)

21. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

22. HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects from the ICONA Italian Cohort of HIV-Infected Patients

24. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

25. Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study

26. Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure

28. Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy

29. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort

31. Switching from TDF to TAF or dual therapy (DT)-based regimens in HIV-infected individuals with viral load <= 50 copies/ml: does eGFR matter?

35. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL

36. Drop in CD4+ counts below 200 cells/µL after reaching (or starting from) values higher than 350 cells/µL in HIV‐infected patients with virological suppression

37. Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA project

39. Effectiveness and safety of cobicistat-boosted darunavir-based antiretroviral treatment in an Italian observational cohort: the TMC114FD1HTX4003 (STORE.) study

40. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance

41. Serius liver events and liver-related deaths in HIV/HCV co.infected patients with diabetes: data from the ICONA Founfation Cohort Study

43. Predictors of severe weight gain in patients treated with Dolutegravir

45. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort

46. Dolutegravir safety in a real-life setting: results from the SCOLTA cohort

50. Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort

Catalog

Books, media, physical & digital resources